TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Allergy Therapeutics ( (GB:AGY) ) is now available.
Allergy Therapeutics has announced new long-term incentive awards for its senior executive team and share option awards for all employees. These awards aim to incentivize share price growth and operational performance over five years, with specific performance targets set. The initiative reflects the company’s strategy to enhance its market position and shareholder value.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy vaccines. The company focuses on developing and delivering immunotherapies to treat allergies, aiming to accelerate sales and enhance shareholder value.
Average Trading Volume: 459,826
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £309.8M
See more insights into AGY stock on TipRanks’ Stock Analysis page.